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Although chemotherapy targets cancer tissue, it also damages the DNA of non-cancer cells. The aim 
of this study was to evaluate the in vitro genotoxic potential of therapeutic concentrations of bleomycin 
and mitomycin C, added alone or in combination to cultures of human peripheral lymphocytes. The 
levels of DNA damage and repair were assessed using the alkaline comet assay immediately after cell 
treatment as well as 24 and 48 hours following treatment. The results indicate that individual drugs and 
their combination induce a significant DNA damage to peripheral blood lymphocytes. Bleomycin alone 
induced the highest levels of primary DNA damage immediately after cell treatment. Although mitomycin 
C alone induced massive cross-linking and retarded DNA migration in resting cells, active proliferation 
and repair processes significantly increased DNA damage. Combined, they showed a synergetic effect, 
inducing complex patterns of DNA damage in peripheral blood lymphocytes and producing different 
types of lesions and a number of DNA alterations that directly or indirectly increased DNA migration. Our 
study has confirmed the sensitivity of the alkaline comet assay for assessing bleomycin and/or mitomycin 
C genotoxicity to human lymphocytes at concentration levels used in clinic. It has also demonstrated the 
utility of the alkaline comet assay as one of the primary screening methods for in vitro studies of drug-
DNA interactions, especially in studying mechanisms of action of new drugs.
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Cytotoxic drugs are a unique therapeutic class 
of fundamental importance in current antineoplastic 
chemotherapy. They belong to different chemical 
and chemotherapeutic classes. Many of them are 
genotoxic, carcinogenic and teratogenic when tested 
in vivo and in vitro (1, 2). Patients suffering from 
disseminated malignant diseases are often treated 
with a combination of antineoplastic drugs which 
have considerable side effects in cell lines expressing 
higher growth and replication rates. Mutagenic 
treatment of a primary cancer may further increase 
the risk of the development of a secondary cancer, as 
it induces heritable alterations of tumour-associated 
genes. Different studies have shown that patients in 
successful remission have a higher risk for secondary 
malignancies, including leukaemia and solid tumours. 
Their incidence correlates with the type of treatment 
patients received; those experiencing the most 
intensive treatment run the highest risk (3).
Bleomycin and mitomycin C are potent and 
widely used antineoplastic antibiotics. Bleomycin is 
used either in monotherapy or in combination therapy 
to treat several malignancies including soft tissue 
carcinomas, squamous cell carcinoma, testicular 
tumours, non-Hodgkin’s lymphoma, and Kaposi 
sarcoma (4-8). It is described as a radiomimetic 
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agent capable of inducing single- and double-strand 
breaks in DNA - with consequent chromosome 
aberrations - in all phases of the cell cycle (9, 10). 
Cells in the M and G2 phase are the most sensitive to 
bleomycin toxicity (11). It induces a wide spectrum of 
mutagenic lesions in mammalian cells, including DNA 
base damage and apurinic/apyrimidinic sites and is 
also capable of cleaving RNA (12-14). Mitomycin C is 
an important component in combined chemotherapy 
of breast, lung, and prostate cancer, and is among 
the few drugs effective against colorectal cancer 
and superficial bladder cancer (15). It also produces 
many biological effects in mammalian cells or 
microorganisms: selective inhibition of DNA synthesis, 
recombination, chromosome breakage, induction of 
sister chromatid exchanges and DNA repair (SOS 
response) in bacteria (16-22). Mitomycin C mainly 
alkylates the N-2 position of guanine, upon reductive 
activation cascade, to form either monoadducts or 
intra- or interstrand cross-links (23). Since interstrand 
cross-links prevent DNA strand separation and can 
completely block DNA replication and transcription, 
the toxicity of mitomycin C has mainly been correlated 
with the formation of these adducts (15). 
Despite extensive research, the mechanisms 
of action of bleomycin and mitomycin C are still 
controversial and the molecular basis of their 
genotoxicity has yet to be understood. Although a 
precise definition of “genotoxicity” is elusive, there 
is no doubt that DNA damage plays an important 
role in most mechanisms underlying the action of 
anticancer drugs interacting with DNA. It is therefore 
an imperative task in chemotherapy to determine the 
DNA-damaging effect of these drugs in normal cells 
(24). Because of their accessibility, human peripheral 
lymphocytes are among the most frequently studied 
“normal” human cells. They are often used as an 
indicator of DNA damage and are most commonly 
tested using the comet assay (25). This study used 
lymphocyte cultures as a model system because 
their growth patterns are similar to those observed 
in malignant tumours, where not all cells are in the 
same phase of the cell cycle.
The aim of our study was to evaluate in vitro the 
genotoxicity of bleomycin and mitomycin C, alone 
or combined using the alkaline comet assay as a 
simple method for the assessment of DNA damage 
and repair. This method has been well documented 
to allow sensitive detection of primary DNA lesions 




Peripheral blood was obtained from a healthy male 
donor (age 22 years, non-smoker). The donor had 
not been exposed to ionizing or non-ionizing radiation 
for diagnostic or therapeutic purposes and to known 
genotoxic chemicals for a year sampling. The blood 
sample (V=20 mL) was collected by venipuncture into 




Stock solutions of bleomycin (Bleocin, Nippon 
Kayaku Co., Ltd) and mitomycin C (Mitomycin C, 
Sigma) were prepared in sterile bi-distilled water. 
Final concentrations in culture were 0.39 µg/mL for 
bleomycin and 0.31 µg/mL for mitomycin C. These 
doses are within the therapeutic range (15 mg/m2 for 
bleomycin and 12 mg/m2 for mitomycin C).
Cell cultures
Lymphocyte cultures were established from freshly 
drawn heparinized blood. Whole blood (V=0.8 mL) 
was added to 8 mL of F-10 tissue culture medium 
(Gibco) containing 20 % foetal bovine serum (Sigma) 
supplemented with penicillin and streptomycin (Pliva). 
The cultures were stimulated with phytohaemagglutinin 
(PHA, Murex; V=0.2 mL).
Bleomycin and mitomycin C treatment
Two different exposure conditions and treatments 
were designed, as follows:
Treatment A (on G0 resting cells that were then 
induced to start the cell cycle). Appropriate volumes of 
bleomycin, mitomycin C and their combination were 
added to lymphocyte cultures at the moment of the 
culture set up. The exposure lasted 24 hours.
Treatment B (on proliferating lymphocytes). 
Antineoplastic drugs were added in vitro to 
lymphocyte cultures that had been grown for 24 
hours. The exposure lasted 24 hours.
After 24-hours of exposure, media containing 
antineoplastic drugs were carefully removed. 
Lymphocytes were re-suspended in fresh tissue 
culture media and cultivated in vitro for another 48 
hours.
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computer-based image analysis system (Comet Assay 
II, Perceptive Instruments Ltd., U.K.). To avoid the 
variability, one well-trained scorer scored all comets. 
Three parameters of DNA damage were analysed: 
tail length (presented in micrometres), tail DNA (%) 
and tail moment.
Statistical analysis
Statistical analyses were carried out using 
Statistica 5.0 for Windows (StatSoft, Tulsa, USA). 
The extent of DNA damage was analysed considering 
the mean (± standard error of the mean), median, 
range and dispersion coefficient (H) of the comet tail 
length. Dispersion coefficient was calculated as the 
ratio between sample variance and sample mean to 
determine the effect of exposure on the distribution 
of comet tail lengths within each sample. Cells were 
also classified as either “undamaged” or “damaged” 
with respect to threshold levels indicating comets with 
a long-tailed nucleus (LTN), i.e. the length over the 
95th percentile of the distribution of the tail parameters 
among control samples (31). Multiple comparisons 
between groups were done using multifactor ANOVA. 
In order to normalise distribution and to equalize 
variances, data were log-transformed [x’ = log (x+1)]. 
Post-hoc analysis of differences was done using the 
Scheffé test. The level of statistical significance was 
set at P<0.05.
RESULTS AND DISCUSSION
The results of this study are summarised in Tables 
1 (treatment A) and 2 (treatment B), showing the mean 
values and medians for each sample analysed. As the 
comet measurements were not normally distributed, 
the results are also presented as the frequency 
distributions of comet tail lengths derived from the 
measurement of 100 nuclei per sample. Histograms 
showing the frequency distribution of comets with 
regard to their tail lengths are shown in Figures 1 
(treatment A) and 2 (treatment B). Figure 3 shows 
comets in treated and control samples. 
The alkaline comet assay detected even subtle 
differences in DNA migration in normal untreated 
lymphocytes. The results shown in Tables 1 and 
2 and in Figures 1 and 2 indicate that untreated 
lymphocytes exhibited different levels of primary DNA 
damage, depending on their position in the cell cycle. 
These results are in accordance with data obtained 
In both experiments one culture was left untreated 
for negative control (i.e. no drug was added). Control 
culturing followed the same procedure as all other 
cultures (with regard to the replacement of fresh 
medium). 
DNA damage and repair were evaluated using the 
alkaline comet assay immediately after the treatment, 
as well as 24 and 48 hours after the treatment. For this 
purpose, aliquots of 10 µL lymphocyte suspensions 
were taken and microgels were prepared in sterile 
conditions.
The alkaline comet assay
The comet assay was carried out under alkaline 
conditions, as described by Singh et al. (30). Two 
parallel replicate slides per sample were analysed. 
Agarose gels were prepared on fully frosted slides 
coated with 1 % and 0.6 % normal melting point 
(NMP) agarose (Sigma). Lymphocyte samples (5 
µL) were mixed with 0.5 % low melting point (LMP) 
agarose (Sigma), placed on the slides and covered 
with a layer of 0.5 % LMP agarose. The slides were 
immersed for 1 h in freshly prepared ice-cold lysis 
solution [2.5 mol/L NaCl, 100 mmol/L Na2EDTA, 10 
mmol/L Tris-HCl, 1 % Na-sarcosinate (Sigma), pH 
10] with 1 % Triton X-100 (Sigma) and 10 % dimethyl 
sulfoxide (Kemika). Denaturation and electrophoresis 
were carried out at 4 °C under dim light in freshly 
prepared electrophoretic buffer (300 mmol/L NaOH, 
1 mmol/L Na2EDTA, pH 13.0). After 20 min of 
denaturation, the slides were randomly placed side 
by side in the horizontal gel-electrophoresis tank, 
facing the anode. Electrophoresis at 25 V (300 mA) 
lasted another 20 min. The slides were then gently 
washed with a neutralisation buffer (0.4 mol/L Tris-
HCl, pH 7.5) three times at five-minute intervals. 
Ethidium bromide (20 µg/mL) was used for staining 
and the slides were stored at 4 °C in humidified sealed 
containers until analysis.
Comet capture and analysis
Each slide was examined using a 250x magnification 
fluorescence microscope (Zeiss, Germany) equipped 
with an excitation filter of 515-560 nm and a barrier 
filter of 590 nm. A total of 100 comets per sample were 
scored (50 from each of two replicate slides). Comets 
were randomly captured at a constant depth of the gel, 
avoiding the edges of the gel, occasional dead cells 
and superimposed comets. Using a black and white 
camera, the microscope image was transferred to a 
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Table 1  Results of the alkaline comet assay on control peripheral blood lymphocytes and lymphocytes treated with bleomycin (0.39 µg/mL), 
mitomycin C (0.31 µg/mL) and their combination in vitro for 24 hours. Antineoplastic drugs were added to the cell cultures at the moment 
of culture initiation (treatment A).
TAIL LENGTH / µm TAIL DNA % TAIL MOMENT ΣA 
/100 
cells Min. Max. Mean ±S.E. Median H LTN Min. Max. Mean ±S.E. Median Min. Max. Mean ±S.E. Median
Bleomycin
1 15.38 97.43 36.47±1.80a 30.13 8.99 83 <0.01 28.45 7.07±0.74b 4.30 <0.01 7.04 1.34±0.15a 0.83 -
2 13.46 96.79 25.45±1.34b 20.83 7.09 59 <0.01 19.20 4.64±0.51b 2.81 <0.01 8.11 0.79±0.12b 0.42 4
3 13.46 41.02 20.56±0.48 19.23 1.10 65 <0.01 10.79 1.35±0.22 0.46 <0.01 1.88 0.22± 0.04 0.07 2
Mitomycin C
1 13.46 50.00 21.61±0.62 19.87 1.77 31 <0.01 29.47 4.35±0.51b 2.82 <0.01 4.16 0.69± 0.08 0.40 -
2 12.82 57.69 23.73±0.93c 20.51 3.65 61 <0.01 22.88 5.01±0.54b 3.29 <0.01 5.53 0.89± 0.10c 0.54 2
3 11.54 51.92 20.35±0.67 18.59 2.19 58 <0.01 14.95 1.95±0.28 0.91 <0.01 2.19 0.30±0.04 0.14 3
Bleomycin + Mitomycin C
1 14.74 91.02 30.96±1.50b 26.28 7.30 71 <0.01 21.89 3.87±0.50b 2.17 <0.01 3.93 0.72±0.09 0.39 -
2 14.74 67.31 29.70±1.17b 26.28 4.58 82 0.01 27.10 5.28±0.56b,d 3.16 <0.01 4.17 0.86±0.09c 0.53 5
3 12.18 74.36 21.72±1.08 18.59 5.35 53 <0.01 9.99 1.90±0.23 0.91 <0.01 2.39 0.33±0.05 0.12 4
Control
1 15.38 46.79 22.77±0.53a 17.63 0.46 5 <0.01 25.89 5.53±0.65a 1.81 <0.01 3.65 0.85±0.09a 0.28 -
2 12.82 30.77 18.10±0.29b 15.38 0.36 4 <0.01 9.86 2.53±0.24b 0.25 <0.01 1.39 0.38±0.04b 0.04 1
3 10.26 23.72 15.41±0.24 14.74 0.12 1 <0.01 5.83 0.83±0.13 0.11 <0.01 0.97 0.12±0.02 0.01 1
Data based on 100 comet measurements per sample. 1,2,3 - time of sampling; 1 – immediately after treatment; 2 – 24 hours after treatment; 
3 – 48 hours after treatment. H – dispersion coefficient; LTN – Long-tailed nuclei; A-apoptosis.
Statistical significance of the results was evaluated on log-transformed data using ANOVA. Post-hoc comparisons were made using the Scheffé test. 
Significantly increased values (P<0.05) are marked with letters a-d. (a) Significantly higher than in samples 2 and 3; (b) significantly higher than in 
sample 3; (c) significantly higher than in samples 1 and 3; (d) significantly higher than in sample 1.
Table 2  Results of the alkaline comet assay on control peripheral blood lymphocytes and lymphocytes treated with bleomycin (0.39 µg/mL), 
mitomycin C (0.31 µg/mL) and their combination in vitro for 24 hours. Antineoplastic drugs were added into the cell cultures after 24 hrs 
of lymphocyte growth in vitro (treatment B).
TAIL LENGTH / µm TAIL DNA % TAIL MOMENT ΣA 
/100 
cellsMin. Max. Mean ±S.E. Median H LTN Min. Max. Mean ±S.E. Median Min. Max. Mean ±S.E. Median
Bleomycin
1 15.38 85.90 29.93±1.49a 24.36 7.42 53 0.01 28.91 5.28±0.69b 2.02 <0.01 7.81 1.05±0.16b 0.36 8
2 12.18 35.26 16.60±0.38 16.03 0.85 8 <0.01 14.98 1.68±0.31 0.44 <0.01 3.46 0.26±0.05 0.07 -
3 12.82 142.30 28.03±2.76c 17.95 27.25 49 <0.01 29.19 4.43±0.61b 1.98 <0.01 16.28 1.02±0.24b 0.29 5
Mitomycin C
1 20.51 78.20 34.11±1.08c 30.45 3.40 87 0.08 23.72 5.18±0.47c 4.13 0.02 5.63 1.02±0.10c 0.76 8
2 10.26 34.61 15.88±0.42 14.74 1.14 12 <0.01 18.58 1.98±0.35 0.47 <0.01 2.98 0.28±0.05 0.07 -
3 13.46 157.05 36.12±2.40c 29.17 15.99 85 <0.01 21.20 5.96±0.62c 2.90 <0.01 6.22 1.07±0.12c 0.56 5
Bleomycin + Mitomycin C
1 21.79 98.72 40.11±1.59c 35.26 6.28 94 0.51 24.14 7.39±0.61c 5.46 0.11 6.50 1.43±0.13c 0.95 5
2 9.62 28.85 16.12±0.37 15.38 0.84 12 <0.01 9.81 1.51±0.23 0.38 <0.01 1.45 0.23±0.04 0.05 -
3 15.38 139.10 53.90±2.57d 50.96 12.25 97 <0.01 32.13 9.11±0.80c 6.69 <0.01 8.39 1.93±0.18c 1.39 -
Control
1 11.54 28.85 17.37±0.28a 17.31 0.46 4 <0.01 4.94 1.20±0.13 0.75 <0.01 0.86 0.19±0.02 0.10 1
2 10.90 36.54 15.10±0.34 14.10 0.77 5 <0.01 7.94 0.87±0.16 0.20 <0.01 1.33 0.13±0.03 0.03 1
3 12.18 20.51 15.33±0.15 14.74 0.15 3 <0.01 8.00 0.85±0.14 0.17 <0.01 1.23 0.12±0.02 0.02 1
Data based on 100 comet measurements per sample. 1,2,3 - time of sampling; 1 – immediately after treatment; 2 – 24 hours after treatment; 
3 – 48 hours after treatment. H – dispersion coefficient; LTN – Long-tailed nuclei; A-apoptosis. 
Statistical significance of the results was evaluated on log-transformed data using ANOVA. Post-hoc comparisons were made using the Scheffé test. 
Significantly increased values (P<0.05) are marked with letters a-d. (a) significantly higher than in samples 2 and 3; (b) significantly higher than in 
sample 3; (c) significantly higher than in sample 2; (d) significantly higher than in samples 1and 2.
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elsewhere using the alkaline comet assay (32, 33). 
However, the background levels of lymphocyte DNA 
damage were significantly modified after exposure to 
antineoplastic drugs.
Genotoxicity of bleomycin. Bleomycin induced 
high levels of primary DNA damage, both in resting 
and proliferative lymphocytes. The damage levels in 
treated lymphocytes were significantly higher than in 
control samples (Tables 1 and 2). The comparison 
showed significant differences between treatments 
A and B and no consistent pattern. However, the 
levels of DNA damage significantly decreased when 
treated lymphocytes were incubated for 24 hours in 
fresh growth media.
As shown in histograms (Figures 1 and 2) DNA 
damage substantially varied between treated cells. A 
right-hand shift in the distribution of comet parameters 
in bleomycin- treated cells is interpreted as an increase 
in DNA damage. The values of dispersion coefficient 
(H) for treated samples were also high. On the other 
hand, frequency distribution in control samples was 
more homogenous, and the H values were significantly 
lower (Tables 1 and 2).
Different studies confirmed that the onset of 
detectable damage in the alkaline comet assay 
depends on the mechanisms of action of DNA-
damaging agents (34,35). In our investigation, 
the highest level of DNA damage was observed 
immediately after bleomycin treatment. Such a high 
positive response to the treatment with bleomycin 
was also observed in other studies (34-40). This may 
be due to a wide spectrum of primary DNA lesions, 
but also to indirectly induced intracellular oxidative 
stress leading to the formation of additional alkali-
labile apurinic/apyrimidinic sites that are effectively 
detected by the comet assay.
A reduction in DNA damage observed in later 
measurements in our study points to DNA repair. Most 
Figure 1  Distribution of comet tail lengths in control lymphocytes and lymphocytes treated with bleomycin and/or mitomycin C for 24 hours. 
Antineoplastic drugs were added to cultures in the following concentrations: 0.39 µg/mL for bleomycin and 0.31 µg/mL for mitomycin 
C. Treatments lasted 24 hours. Antineoplastic drugs were added to cell cultures at the moment of culture initiation (treatment A). 1,2,3 
– time of sampling; 1 – immediately after treatment; 2 – 24 hours after treatment; 3 – 48 hours after treatment
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of the primary DNA lesions induced by bleomycin were 
effectively repaired 24 hours after the treatment (Tables 
1 and 2). Similar observations have also been reported 
by other authors (38, 39, 41). The repair kinetics of 
treated lymphocytes in our study strongly depended 
on their proliferative status. The same was observed 
in other studies, indicating that mitogen stimulation 
of lymphocytes may result in an increased removal of 
specific types of DNA lesions. This observation might 
be explained by cell-cycle-dependent regulation of 
specific DNA repair enzymes, which are more active 
in proliferative than in resting cells (42, 43). During the 
post-treatment period, we also observed late effects 
of bleomycin exposure. They might be related to the 
depletion of the cell culture medium, production of 
clusters of lesions or multiply damaged sites (MDS) 
as well as to ineffective repair mechanisms. There 
is strong evidence that MDS have the potential for 
conversion to lethal lesions (44) while unrepaired DNA 
damage caused by bleomycin triggers apoptosis, that 
is, programmed cell death (9, 11). Similar has been 
observed in our study.
Genotoxicity of mitomycin C. In our study, 
mitomycin C induced different damage levels and 
different repair kinetics from bleomycin. The levels of 
primary DNA damage recorded in resting lymphocytes 
exposed to mitomycin C were significantly lower than 
in those treated with bleomycin and even lower than in 
corresponding control (Table 1). These observations 
are in accordance with earlier reports using standard 
alkaline comet assay which show that mitomycin C 
usually causes no increase or even decreased DNA 
migration  (18, 23, 45).
In contrast, active cell proliferation significantly 
increases DNA migration and the levels of DNA 
damage. Although retarded DNA migration was 
Figure 2  Distribution of comet tail lengths in control lymphocytes and lymphocytes treated with bleomycin and/or mitomycin C for 24 hours. 
Antineoplastic drugs were added to cultures in the following concentrations: 0.39 µg/mL for bleomycin and 0.31 µg/mL for mitomycin 
C. Treatments lasted 24 hours. Antineoplastic drugs were added to cell cultures after 24 hrs of lymphocyte growth in vitro (treatment B). 
1,2,3 – time of sampling; 1 – immediately after treatment; 2 – 24 hours after treatment; 3 – 48 hours after treatment.
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recorded in resting lymphocytes, proliferative 
lymphocytes were more susceptible to mitomycin 
C. Immediately after treatment, their tail lengths, tail 
DNA %, tail moments, and the number of long tailed 
and apoptotic nuclei significantly increased (Table 2). 
Increased DNA migration in stimulated cells has also 
been reported by other investigators (42, 43). 
Our results also confirmed earlier findings 
indicating that the repair of alkylated damage during 
the post-treatment period essentially contributed to 
DNA migration in mitomycin C-treated cells (Tables 
1 and 2). When interstrand cross-links undergo 
nucleotide excision repair, additional breaks and 
alkali-labile sites are generated that are sensitively 
detected by the alkaline comet assay. Earlier reports 
show that mitomycin C-induced cross-links take at 
least 24 hours to repair completely and after their 
removal, cells displayed damage comparable to that 
shown by control cells (46). This study confirms 
these observations. Furthermore, our results are also 
consistent with reports (36) suggesting that cross-links 
induced by mitomycin C are not readily detected by the 
standard version of the alkaline comet assay because 
their migration-reducing effect is overwhelmed by the 
migration-inducing effect of other lesions. Therefore, 
the level of alkylation-induced damage as detected 
by the standard alkaline comet assay is a measure 
of DNA repair events, not of actual damage (36). 
Other authors reported that the repair of mitomycin 
C-induced lesions is often accompanied by a cell-cycle 
delay in S and/or G2 phase (15,18). Interstrand cross-
links caused by mitomycin C greatly distort the DNA 
structure and cause catastrophic consequences for a 
cell if unrepaired (47), and unrepaired DNA damage 
triggers apoptosis (15). In our study apoptotic nuclei 
were found after treatment with mitomycin C and their 
number was the highest in lymphocytes treated during 
active proliferation (Table 2).
Combined genotoxicity of bleomycin and 
mitomycin C. Combined treatment with both 
antineoplastic drugs showed a considerable variability 
in the pattern of lymphocyte DNA damage and repair. 
Our results suggest that bleomycin and mitomycin 
C synergetically induced DNA damage in peripheral 
blood lymphocytes (Tables 1 and 2). A comparison 
showed significant differences between treatments A 
and B. Depending on the position in the cell cycle, 
lymphocytes significantly differed in sensitivity to 
combined treatment. Moreover, the damage was 
significantly greater than in corresponding control cells 
(Tables 1 and 2). Adding both drugs to lymphocyte 
cultures produced different types of damage: single 
strand breaks, alkali labile sites and cross-links, but 
also a number of additional DNA alterations that 
might increase DNA migration. Resting lymphocytes 
simultaneously exposed to both drugs (treatment A) 
displayed significantly higher levels of primary DNA 
damage than those exposed to mitomycin C alone, but 
lower than those exposed to bleomycin alone (Table 
1). This observation points to a possible retardation 
of DNA migration caused by the cross-linking activity 
Figure 3  Lymphocyte comets after in vitro exposure to bleomycin 
(BLM) or mitomycin C (MMC), or their combination. The 
concentrations were 0.39 µg/mL for BLM and 0.31 µg/mL 
for MMC. Treatments lasted 24 hours. (a) immediately after 
treatment A with BLM most comets had long tails containing 
a low fraction of highly fragmented DNA. (b) 48 hours after 
treatment B with BLM comet tails significantly decreased 
due to DNA repair. (c) immediately after treatment A with 
MMC most comets had short tails containing a high fraction 
of DNA. (d) 48 hours after treatment B with MMC various and 
untypical comet shapes were observed because DNA cross-
linking prevented highly fragmented DNA from migrating 
during gel electrophoresis. (e) immediately after treatment 
A with BLM and MMC lymphocyte comets with untypical 
shapes were observed. (f, g) 48 hours after treatment B with 
BLM and MMC a number of comets with long tails containing 
a high fraction of DNA were observed. (h) Control lymphocytes 
had comets with very short tails or without any.
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of mitomycin C in combined exposure. Proliferative 
lymphocytes (treatment B) were very susceptible to 
DNA damage caused by the combination of drugs 
(Tables 1 and 2). They displayed a significantly 
higher level of primary DNA damage than bleomycin 
and mitomycin C used alone (Table 2). Combined 
treatment also led to a high number of long tailed 
and apoptotic nuclei (Tables 1 and 2).
Our results point out that combined application 
of these drugs is highly effective in therapy, which is 
desirable in proliferative cancer cells, but not in non-
cancer cells that unavoidably suffer severe genetic 
damage during and after chemotherapy. Our study 
also suggests that the kinetics of DNA repair strongly 
depends on lymphocyte proliferative status. The 
combined effects of bleomycin and mitomycin C are 
complex. It was reported earlier that the evaluation of 
the comet assay may be difficult where DNA lesions 
are accompanied by cross-links, since the test results 
will be a combination of inhibiting and inducing effects 
on DNA migration (48). The same was observed in our 
study in lymphocytes treated with both antineoplastic 
drugs.
The combined use of drugs, as opposed to 
monotherapy, has become a standard in modern 
chemotherapy of cancer. However, to achieve 
maximum therapeutic effect, these agents are used 
in high doses, and are often highly genotoxic to 
normal cells. Their ability to induce DNA damage in 
non-cancer cells may account for one of the most 
serious side effects produced by anticancer drugs 
– the induction of secondary malignancies (49). 
Although the primary DNA damage is subjected to 
efficient repair processes, some alterations remain 
and may contribute to the development of secondary 
malignancies unrelated to the original neoplasm (50). 
Because only some patients receiving a chemotherapy 
develop secondary cancer, it is important to determine 
whether they are hypersensitive to the treatment and 
whether this sensitivity may be indicative of the 
risk of the secondary cancer (3). For this reason, 
it is necessary to study certain biological markers 
that could be used as early predictors of disease 
progression and outcome. Since the effects of specific 
compounds are often tissue and cell-type related, it is 
important to develop, validate and apply techniques 
that can detect DNA damage at the single-cell level 
(30). The alkaline comet assay seems to fulfil this 
purpose.
CONCLUSION
This study has achieved its aim and we were able 
to demonstrate the correlation between the alkaline 
comet assay and the response to treatment. The results 
obtained suggest that therapeutic concentrations of 
bleomycin and mitomycin C applied in vitro alone 
and in combination can significantly increase primary 
DNA damage in human lymphocytes. The analysis of 
DNA repair kinetics confirmed different patterns of 
DNA damage when the drugs were used alone and in 
combination. We also observed significant differences 
in DNA damage induction and repair with respect to 
the lymphocyte proliferative status and their position 
in the cell cycle. It is quite possible that similar levels 
of DNA damage are also induced in non-cancer cells 
of patients who received bleomycin and mitomycin C 
during chemotherapy. However, the pharmacokinetics 
of antineoplastic drugs is different in vivo; they do 
not fully bind or interact with DNA and the drug 
metabolism in the liver also affects its action.
Despite limitations, our results show that the 
alkaline comet assay is a useful screening method 
for in vitro studies of drug-DNA interactions, especially 
for studying mechanisms of action of new drugs. 
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Saetak
PROCJENA GENOTOKSIÈNOSTI BLEOMICINA I MITOMICINA C METODOM KOMETNOG 
TESTA 
Veæina antineoplastiènih lijekova ima nespecifièno djelovanje pa su na njihovu primjenu osjetljive i stanice 
zdravog tkiva. U pretklinièkim istraivanjima lijekova vanu ulogu imaju brzi i osjetljivi testovi za procjenu 
razina ošteæenja i popravka staniène DNA. Cilj istraivanja bio je procijeniti toksièke uèinke bleomicina i 
mitomicina C na genom ljudskih limfocita u uvjetima in vitro primjenom kometnog testa u alkalnoj izvedbi. 
Limfociti su 24 h izlagani pojedinaènim lijekovima te njihovoj kombinaciji u terapijskim koncentracijama, a 
potom je praæena dinamika ošteæenja i popravka DNA. Postavljena su dva pokusa: (A) u kojem su lijekovi 
dodavani u trenutku uspostavljanja staniènih kultura kako bi se procijenili toksièki uèinci na limfocite u fazi 
mirovanja i poèetnim fazama rasta, i (B) u kojem su lijekovi dodavani nakon 24 h rasta stanica u kulturi, 
kako bi se istraili uèinci na stanice u diobi. Rezultati istraivanja pokazuju da oba lijeka izazivaju znaèajna 
primarna ošteæenja limfocitne DNA. Razine ošteæenja i dinamika njihova popravka ovisne su o diobenoj 
aktivnosti limfocita i njihovu poloaju unutar staniènog ciklusa. Ošteæenja izazvana bleomicinom vrlo su 
jaka neposredno nakon tretmana, a u kasnijim fazama rasta limfocita veæinom se popravljaju. Mitomicin 
C izaziva drukèiji obrazac ošteæenja i popravka DNA. Zbog ukrienog povezivanja izmeðu lanaca DNA, on 
znaèajno usporava migraciju DNA tijekom elektroforeze u alkalnim uvjetima, a visoke razine ošteæenja koje 
se detektiraju u kasnijim fazama rasta uzrokovane su procesima popravka DNA. Bleomicin i mitomicin C 
sinergistièki izazivaju opsena ošteæenja limfocitne DNA, osobito u diobeno aktivnim stanicama. Dobiveni 
rezultati govore u prilog primjene kometnog testa u pretklinièkim istraivanjima antineoplastiènih lijekova 
i upuæuju na moguæu primjenu ove metode u procjeni ošteæenja genoma proizašlih iz izloenosti ovim 
agensima.
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